AbbVie Inc. announced Monday that it will acquire Apogee Therapeutics Inc. for $10.9 billion [1] in an all-cash transaction.
The deal allows the North Chicago-based company to bolster its anti-inflammatory portfolio and dermatology pipeline. This move comes as AbbVie faces increasing competition for its best-selling drug, necessitating a push into next-generation immunology growth [3].
Apogee Therapeutics, based in Waltham, Massachusetts, specializes in immunology drug development [4]. As part of the acquisition, AbbVie will gain an experimental treatment designed for patients with moderate-to-severe atopic dermatitis [1].
Financial terms of the agreement include a per-share price of $135.11 [2]. The companies expect the transaction to close during the third quarter of 2026 [2].
By integrating Apogee's research and development, AbbVie aims to diversify its therapeutic offerings. The addition of the atopic dermatitis candidate strengthens the company's position in the dermatology market, a key area of growth for the pharmaceutical giant [3].
The acquisition follows a broader industry trend of large pharmaceutical firms purchasing smaller biotech companies to secure promising drug candidates. This strategy reduces the risk of internal research failure by acquiring assets that have already reached experimental stages [1].
“AbbVie will purchase Apogee Therapeutics for $10.9 billion in cash.”
This acquisition signals AbbVie's urgency to replace revenue streams as its legacy blockbuster drugs face stiffer competition and patent challenges. By investing heavily in Apogee's specialized immunology platform, AbbVie is pivoting toward high-growth dermatology markets to maintain its market leadership in chronic inflammatory diseases.
